

# DC CTSA Spring Regulatory Update & Hot Topics in Clinical and Translational Research

*Beyond COVID-19: Challenges & Lessons Learned during a Pandemic*

## Dissemination of Research During the Pandemic

Moderator: Sarah Vittone, DBe, MA, MSN, RN

Doctor of Bioethics  
Assistant Professor, School of Nursing and Health Studies  
Georgetown University

11:30 AM - 12:25 PM EST



THE GEORGE  
WASHINGTON  
UNIVERSITY  
WASHINGTON, DC



# DC CTSA Spring Regulatory Update & Hot Topics in Clinical and Translational Research

*Beyond COVID-19: Challenges & Lessons Learned during a Pandemic*

## **Dissemination of Research During the Pandemic**



**Lars Berglund, M.D., Ph.D.**

Editor  
Journal of Clinical and Translational Science



**Theodora Bloom, Ph.D.**

Executive Editor  
The BMJ

# JCTS and COVID

Lars Berglund MD PhD  
Editor-in-Chief






# JCTS in brief

- Journal started 2017, now in its 5<sup>th</sup> year
- Major focus area: Clinical research; Education; Implementation, Policy and Community Engagement; Translational Research Design and Analysis
- Switched from 6 issues/year to continuous publication in 2021
- Editorial Board largely recruited from CTSA and CTR center institutions
- Junior editors – APSA and KL2 trainees
- In 2020 initiated thematic issues: 3 published, 3 under way including one focused on COVID-19, and several in planning stage




## Original Submissions Received – last 5 years





# JCTS new submissions 2020



■ Reviews      ■ Perspectives      ■ Special Comm      ■ Research Articles  
■ Brief Reports      ■ Editorials      ■ Expedited reports      ■ Letters





# JCTS – changes made due to COVID-19

- In April 2020, initiated a rapid review pathway for COVID-related submissions – goal to review within 7 days
- Engaged Editorial Board to be onboard with rapid turnaround
- No major change regarding review process beyond the shorter timeline – criteria same as for regular submissions
- After discussions with Cambridge University Press (publisher) offered waiving submission fees for COVID-related submissions
- Waiver initially lasting until September, continued until end of December 2020
- In the fall of 2020, due to volume, we reverted back to a single review process for all submissions





# JCTS – COVID vs non-COVID submissions


- Between April 2020 – March 2021 we received 203 submissions, of which 50 were COVID manuscripts (25%).
- COVID submissions to date – 33 accepted and 10 rejected – rejection rate 23%
- Non-COVID submissions to date – 72 accepted and 22 rejected – rejection rate 23%
- Under review or in revision – 7 COVID paper and 59 non-COVID papers
- COVID papers had shorter timeline – 30 vs 46 days to first decision and 46 vs 74 days to final decision







The chart below shows the number of full-text downloads and abstract views annually from January 2017 – March 26<sup>th</sup>, 2021.





# Of top 10 downloaded papers – 7 addressed COVID

Popular papers on Cambridge Core – Top 25 articles by number of fulltext downloads, 1 January 2020 to 31 December 2020

Article Title	Author(s)	Vol:Iss	Downloads
Safety of influenza vaccine during COVID-19	Zein et al.	5	9,805
The potential for antibody-dependent enhancement of SARS-CoV-2 infection: Translational implications for vaccine development	Wang & Zand	5	4,712
Clinical characteristics associated with COVID-19 severity in California	Rubin et al.	5	1,963
Leveraging community engaged research partnerships for crisis and emergency risk communication to vulnerable populations in the COVID-19 pandemic	Wieland et al.	5	1,760
Application of volumetric absorptive microsampling (VAMS) to measure multidimensional anti-influenza IgG antibodies by the mPlex-Flu assay	Wang et al.	3:6	1,606
Safety of ACE-I and ARB medications in COVID-19: A retrospective cohort study of inpatients and outpatients in California	Rubin et al.	5	1,383
Effect of various decontamination procedures on disposable N95 mask integrity and SARS-CoV-2 infectivity	Smith et al.	5	1,318
COVID-19 and public health efforts in Mongolia: A lesson maybe learned?	Bayasgalan et al.	5	1,283
Mapping the evolving definitions of translational research	Fort et al.	1:1	1,207
Equipoise and research in the current COVID-19 pandemic	Pulley et al.	5	1,165
Immediate impact of the COVID-19 pandemic on CTSA TL1 and KL2 training and career development	McCormack et al.	4:6	1,078
Optimizing sampling rate of wrist-worn optical sensors for physiologic monitoring	Bent & Dunn	5	1,066
A REDCap-based model for electronic consent (eConsent): Moving toward a more personalized consent	Lawrence et al.	4:4	1,058
Mentoring in crisis does not need to put mentorship in crisis: Realigning expectations	Cameron et al.	5	999
Research on COVID-19 through patient-reported data: a survey for observational studies in the COVID-19 pandemic	Verma et al.	5	965
The digital biomarker discovery pipeline: An open-source software platform for the development of digital biomarkers using mHealth and wearables data	Bent et al.	5	803
Education and training of clinical and translational study investigators and research coordinators: A competency-based approach	Calvin-Naylor et al.	1 :1	749
Advancing health equity through CTSA programs: Opportunities for interaction between health equity, dissemination and implementation, and translational science	Yousefi Nooraie et al.	4:3	631
Comorbidities and health care systems differences among states as it relates to COVID-19	Anderson et al.		596
Building bridges between a community and an academic medical center via community tours	Irby et al.	4:4	571
Career orientation and perceived professional competence among clinical research coordinators	Rojewski et al.	3:5	562
An exploratory study of Clinical and Translational Science Award community-engaged research training programs	Ziegahn et al.	2:2	529
Situating dissemination and implementation sciences within and across the translational research spectrum	Leppin et al.	4:3	525
Pilot study of an intervention to increase cultural awareness in research mentoring: Implications for diversifying the scientific workforce	Byars-Winston et al.	2:2	511
Assessing clinical research coordinator knowledge of good clinical practice: An evaluation of the state of the art and a test validation study	DuBois et al.	4:2	505



# JCTS – COVID thematic issue under way

- Prioritization – COVID vs non-COVID studies
- Virtual visits
- Role of Biorepositories
- Risk/Benefit related to personnel risk and re-opening studies
- Informed consent processes
- Modifying laboratory testing
- IRB procedures
- Role of Informatics
- FDA interactions





# Lessons learned

- Important to offer flexibility
- Engagement of Editorial Board members and Reviewers critical – important stakeholders in process
- Maintaining focus on quality and content in spite of need for speed
- Working with publisher on communication and marketing





# Dissemination of Research in the Pandemic

*2021 DC CTSA Spring Regulatory Update & Hot  
Topics in Clinical and Translational Research Agenda*

Dr Theodora Bloom, Executive Editor, *The BMJ*

# Competing interests


- I'm **Executive Editor of The BMJ**. It is published by BMJ, a wholly owned subsidiary of the British Medical Association.
- BMJ (the company) receives 8.7% of revenues from drug & device companies through advertising, reprint sales, & sponsorship. For *The BMJ* it's 12%. *The BMJ* is an open access journal that charges article-processing fees for Research Articles.
- I chair the Advisory Board of Europe PubMed Central.
- I am a founder of the **MedRxiv clinical preprint server**.
- I am European Coordinator for the quadrennial Peer Review Congress.
- I am on the Board of AIP Publishing



# In an ideal world



# How it worked for 150 years



[https://commons.wikimedia.org/wiki/File:Faraday\\_Michael\\_Christmas\\_lecture.jpg](https://commons.wikimedia.org/wiki/File:Faraday_Michael_Christmas_lecture.jpg)

## MOLECULAR STRUCTURE OF NUCLEIC ACIDS

### A Structure for Deoxyribose Nucleic Acid

WE wish to suggest a structure for the salt of deoxyribose nucleic acid (D.N.A.). This structure has novel features which are of considerable biological interest.

A structure for nucleic acid has already been proposed by Pauling and Corey<sup>1</sup>. They kindly made their manuscript available to us in advance of publication. Their model consists of three intertwined chains, with the phosphates near the fibre axis, and the bases on the outside. In our opinion, this structure is unsatisfactory for two reasons: (1) We believe that the material which gives the X-ray diagrams is the salt, not the free acid. Without the acidic hydrogen atoms it is not clear what forces would hold the structure together, especially as the negatively charged phosphates near the axis will repel each other. (2) Some of the van der Waals distances appear to be too small.


Another three-chain structure has also been suggested by Fraser (in the press). In his model the phosphates are on the outside and the bases on the inside, linked together by hydrogen bonds. This structure as described is rather ill-defined, and for this reason we shall not comment on it.




We wish to put forward a radically different structure for the salt of deoxyribose nucleic acid. This structure has two helical chains each coiled round the same axis (see diagram). We have made the usual chemical assumptions, namely, that each chain consists of phosphate diester groups joining  $\beta$ -D-deoxyribofuranose residues with 3',5' linkages. The two chains (but



But now\*...



\* I think I first showed a slide like this in 2010.




# The case for preprints

- **Speed up science: faster dissemination** within the research community
- Allow pre-publication peer review and feedback, making 'better' articles
- Give authors precedence
- Freely available (but not always fully 'open')
- Surface data that may not survive peer review
- **Risk of surfacing incorrect information, conclusions or assumptions that could be harmful to the health of individuals or whole populations**



<http://asapbio.org/>

# medRxiv: a server for health science preprints



- Conceptually and technologically similar to bioRxiv (basic science, biology)
- Not-for-profit
- A service not a product
- Publisher-neutral
- Operated by CSH Laboratory
- Managed in partnership with BMJ and Yale University
- Launched Q2 2019
- Now supported by CZI



# medRxiv submission requirements:

## Original research articles

- Original clinical/health research, including clinical trials, observational or qualitative research, quality improvement and implementation, policy studies, and medical education
- Systematic reviews and meta-analyses
- Methodological research
- Clinical study Protocols
- Not commentaries, editorials, opinion pieces, essays, letters to editors, narrative reviews, case reports

## Following community norms

- Follow ICMJE guidance
- Funding and competing interests statements
- Statement of IRB / ethics committee oversight
- Study registration when applicable (e.g. ClinicalTrials.gov; PROSPERO)
- Data availability statement
- EQUATOR Network reporting guidelines checklists

# medRxiv: risk mitigation

*Is it nonsense?*

*Is it non-science?*

*Is it a paper?*

*Is it research?*

*Is it plagiarized?*

*Is it a health threat?*

***Is there a benefit to sharing  
now vs. after peer review?***

1

Author undertakings

2

Automated check

3

CSHL Check

4

medRxiv Affiliate check

5

Escalation 1- experienced  
clinician-editor(s)

6

Escalation 2 - medRxiv leadership

7

Posting and public discussion



Cold Spring Harbor Laboratory

BMJ Yale

HOME | ABOUT | SUBMIT | ALERTS / RSS

medRxiv

THE PREPRINT SERVER FOR HEALTH SCIENCES

Search  
Advanced Search

Caution: Preprints are preliminary reports of work that have not been peer-reviewed. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Subject Areas

**Caution: Preprints are preliminary reports of work that have not been peer-reviewed. They should not be relied on to guide clinical practice or health-related behaviors and should not be reported in news media as established information.**

medRxiv

THE PREPRINT SERVER FOR HEALTH SCIENCES



BMJ Yale

HOME | ABOUT | SUBMIT | ALERTS / RSS

Search  
Advanced Search

## Polo like kinase (Plk) 1: A novel target for the treatment of prostate cancer

Marlene Graveland, Tom O'Donnell, Tony Greego'o'oky  
doi: <https://doi.org/10.1101/01001552>

This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.

Abstract Info/History Metrics Preview PDF

## Abstract

Cancer of the Prostate gland (CaP), next only to skin cancer, is the most commonly occurring cancer in American men. The existing treatment approaches and surgical intervention have not been able to effectively manage this dreaded cancer and, therefore, the management processes of the disease need to be improved to provide the best possible outcome for patients.

Previous

Next

Posted January 22, 2019.

Download PDF

Data/Code

Email

Share

Citation Tools

Twitter

Like 0

G+

## Subject Areas

All Articles

Addiction Medicine

**This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.**

medRxiv

THE PREPRINT SERVER FOR HEALTH SCIENCES



BMJ Yale

HOME | ABOUT | SUBMIT | ALERTS / RSS

Search  
Advanced Search

## What is an unrefereed preprint?

Before formal publication in a scholarly journal, scientific and medical articles are traditionally "peer reviewed." In this process, the journal's editors take advice from various experts—called "referees"—who have assessed the paper and may identify weaknesses in its assumptions, methods, and conclusions. Typically a journal will only publish an article once the editors are satisfied that the authors have addressed referees' concerns and that the data presented support the conclusions drawn in the paper.

Because this process can be lengthy, authors use the medRxiv service to make their manuscripts available as "preprints" before peer review, allowing

other scientists to see, discuss, and comment on the findings immediately. Readers should therefore be aware that articles on medRxiv have not been finalized by authors, might contain errors, and report information that has not yet been accepted or endorsed in any way by the scientific or medical community.

We also urge journalists and other individuals who report on medical research to the general public to consider this when discussing work that appears on medRxiv preprints and emphasize it has yet to be evaluated by the medical community and the information presented may be erroneous.

**We also urge journalists and other individuals who report on medical research to the general public to consider this when discussing work that appears on medRxiv and emphasize it has yet to be evaluated by the medical community and the information presented may be erroneous.**

medRxiv is receiving many new papers on coronavirus SARS-CoV-2. A reminder: these are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information.

## COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

15,186 Articles (11,736 medRxiv, 3,450 bioRxiv)

Most recent first

Page 1: Articles 1-10 | Next

### Forecast of the covid19 epidemic in France

Pottier, L.

10.1101/2021.04.13.21255418 — Posted: 2021-04-20

### COVID-19 epidemic scenarios into 2021 based on observed key superdispersion events

Santana-Cibrian, M., Acuna-Zegarra, M.A., Rodriguez Hernandez-Vela, C. E., Velasco-Hernandez, J. X., Mena, R. H.

10.1101/2021.04.14.21255436 — Posted: 2021-04-20

### Impact of vaccination and non-pharmaceutical interventions on SARS-CoV-2 dynamics in Switzerland

Shattock, A. J., Le Rutte, E. A., Duenner, R. P., Sen, S., Kelly, S. L., Chitnis, N., Penny, M. A.

10.1101/2021.04.14.21255503 — Posted: 2021-04-20

### Subject Areas

#### All Articles

Addiction Medicine

Allergy and Immunology

Anesthesia

Cardiovascular Medicine

Dentistry and Oral Medicine

Dermatology

Emergency Medicine

Endocrinology (including Diabetes Mellitus and Metabolic Disease)

Epidemiology


Forensic Medicine

Gastroenterology



# Pandemic growth

Monthly posted:



> 15,000  
total  
posted

> 5,000  
revised  
after  
posting


~ 20%  
rejected

Daily submitted: ->



Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep
9	20	45	92	77	59	57	51	51

# medRxiv Usage by Month



# Widespread recognition of the value of preprints...

[View this email in your browser](#)

Tuesday 1 September 2020



## Europe PMC: unlocking the potential of COVID-19 preprints

30 Jul 2020 - 10:40

### Summary

- Europe PMC is now indexing full-text preprints related to the COVID-19 pandemic, as well as the underlying data
- The project will make COVID-19 scientific literature available in a repository, in a format that allows text mining
- Researchers and healthcare professionals will be able to access this information easily, accelerating research into better treatments or a vaccine

### nature briefing

#### Age is the biggest predictor of who will die

Four studies (three of which have not yet been peer-reviewed) from Spain, England, Italy and Geneva, Switzerland, pinpoint the infection fatality ratio (IFR), which is the proportion of people infected with the virus, including those who didn't get tested or show symptoms, who will die as a result. All found that **the IFR was close to zero in younger**

Reference: [medRxiv preprint 1](#), [medRxiv preprint 2](#), [medRxiv preprint 3](#) & *The Lancet Infectious Diseases* paper

### NIH Preprint Pilot

The NIH Preprint Pilot is a project of the National Library of Medicine (NLM). During the pilot, NLM will make preprints resulting from research funded by the National Institutes of Health (NIH) available via PubMed Central (PMC) and, by extension, PubMed. The pilot aims to explore approaches to increasing the discoverability of early NIH research results posted to [eligible preprint servers](#). PMC already makes available more than one million peer-reviewed papers resulting from NIH-supported research collected under the [NIH Public Access Policy](#). This pilot builds on PMC's NIH repository role as well as 2017 NIH guidance ([NOT-OD-17-050](#)) that encourages investigators to use interim research products, such as preprints, to speed the dissemination and enhance the rigor of their work.

# ... but also worries about their misuse

Covid-19

Scientific research on the coronavirus is being released in a torrent

Will that change how science is published?



All that's fit to preprint

COVID-19 has reinforced the importance of preprints as an indispensable means for rapid research dissemination.  
**Bloomberg Opinion**

Med last year (30,627,413 papers). Thus, larger proportion of one reason why the medical community was so cautious about preprints in the first place. A case in point is bioRxiv's most

Technology & Ideas

## A Pandemic Moves Peer Review to Twitter

The coronavirus has transformed how scientific research findings are communicated. Is that good? Will the changes stick?

APRIL 1, 2020



Strong caveats are lacking as news stories trumpet preliminary COVID-19 research

## Mother Jones

POLITICS ENVIRONMENT CRIME AND JUSTICE FOOD MEDIA INVESTIGATIONS PH

CORONAVIRUS APRIL 28, 2020

### Science Has an Ugly, Complicated Dark Side. And the Coronavirus Is Bringing It Out.

Experts say the pandemic is letting bad science slip through the cracks.



**JACKIE FLYNN MOGENSEN**  
Assistant Editor  
[Bio](#) | [Follow](#)



Date: Tue, 16 Jun 2020 at 15:51

Subject: FOR IMMEDIATE RELEASE: WORLD FIRST CORONAVIRUS TREATMENT APPROVED FOR NHS USE BY GOVERNMENT

To:

**\*\*FOR IMMEDIATE RELEASE\*\***

- Group
- Govi
- oxyg
- Govi

## Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report

[Comments \(17\)](#)

[Previous](#)

Posted June 22, 2020.

Thousands of li  
proven to reduc

Dexamethasone  
including those

The drug has b  
oxygen by 20%

Funded by the l  
University UK R  
patient mortality

The governmen  
positive trial out

Health Secreta

[Peter Horby](#), [Wei Shen Li](#),  
[Natalie Staplin](#), [Christopher](#)  
[Christopher Green](#), [Timothy](#)  
[Lucy C Chappell](#), [Saul N I](#)  
[Edmund Juszczak](#), [J Kenne](#)  
RECOVERY Collaborative Group  
**doi:** <https://doi.org/10.1101/2020.06.11.20114645>

Now published in *New England J*

Abstract

Info/History

### Abstract

Background: Coronavirus  
Corticosteroids may mod

ORIGINAL ARTICLE

# Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report

The RECOVERY Collaborative Group\*

Article

Figures/Media

[Metrics](#)

[39 References](#)

[89 Citing Articles](#)

## Abstract

### BACKGROUND

Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce

July 17, 2020

DOI: 10.1056/NEJMoa2021436

### Related Articles

**EDITORIAL** JUL 17, 2020

Research in the Context of a Pandemic

H.C. Lane and A.S. Fauci

**EDITORIAL** JUL 21, 2020





US Politics Business Tech Science

## President calls negative hydroxychloroquine study 'a Trump enemy statement' - as it happened

medRxiv

THE PREPRINT SERVER FOR HEALTH SCIENCES



HOME | ABOUT

Search

Comments (84)

### Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19

Joseph Magagnoli, Siddharth Narendran, Felipe Pereira, Tammy Cummings, James W Hardin, S Scott Sutton, Jayashri Ambati

doi: <https://doi.org/10.1101/2020.04.16.20065920>

**This article is a preprint and has not been peer-reviewed [what does this mean?]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice.**

Abstract Info/History Metrics

Preview PDF

#### Abstract

**BACKGROUND:** Despite limited and conflicting data on the use of hydroxychloroquine in patients with Covid-19, the U.S. Food and Drug Administration has authorized the emergency use of this drug when clinical trials are unavailable or infeasible. Hydroxychloroquine, alone or in combination with azithromycin, is being widely used in Covid-19 therapy based on anecdotal

# Where is the sweet spot for dissemination?



**Joseph LIM**  
@joseph11lim



Replying to [@bmj\\_latest](#) and [@TheoBloom](#)

Preprints should be let loose only among professionals and peers of researchers, not to the general public. This would still serve to hasten scientific discovery but could help reduce the problems of public mis-understanding or mis-handling of research yet to be peer-reviewed.


9:34 AM · Dec 31, 2020 · Twitter for Android



# The BMJ: print magazine, online journal



- News
  - Features
  - Investigations
  - Education
  - Campaigns
  - Opinions
  - Guidelines
  - Commentary
  - Analysis
  - And Open Access Research
- Articles supported by article-processing charges

BMJ







# BMJ journals portfolio




10,000+  
articles

Number of S1 Research submissions over time from Jan 2017 to end May 2020



# Outline of thebmj review process





4 April 2020  
3691-142 No 8240 | ISSN 1759-2151

thebmj


**Is primary care forever changed?** p 12

**Clinical traits of covid-19 deaths** p 22

**GP guide to remote assessment** p 32

**How to cope with redeployment** p 40

**1 CPD hour in the education section**



**Are we  
doing  
enough  
to protect  
doctors?**



BMJ



## BMJ's Coronavirus (covid-19) Hub

Updated 17 September

All information is freely available

[Guidance](#) [Research from The BMJ](#) [Latest updates](#) [Most read](#) [Latest from BMJ Journals](#)

BMJ's covid-19 hub supports health professionals and researchers with practical guidance, online CPD courses, as well as the latest news, comment, and research from BMJ. The content is free and updated daily.

### Guidance Free

#### Education

##### Testing for SARS-CoV-2 antibodies

How might antibody testing be used?

##### A living WHO guideline on drugs for covid-19

A rapid recommendation on corticosteroids

#### Training

##### Covid-19 related courses

(24 courses)

BMJ Learning offers online courses directly related to

#### Management

##### Covid-19 diagnosis and management

The latest practical guidance from BMJ Best Practice on diagnosis and management of patients with covid-19

##### Clinical decision support

Diagnosis and management of related conditions, with patient information to support shared decision making

#### Patient information

##### Information for patients

Information for patients from BMJ Best Practice

### Infographics Free



#### Covid-19 antibody tests

Updated: 8 Sept

[English](#)



#### Covid-19: Long covid

Updated: 11 August

[English](#)



#### Remote consultation of covid-19

Updated: 25 Mar

[English \(UK\)](#) [English \(US\)](#)


### Latest issue

All information is freely available

# Speeding up journal publication

## REVIEW TIME


An analysis of all papers in PubMed up to 2015 with listed submission and acceptance dates suggests that the median time from submission to acceptance has hovered at around 100 days, although it has gone up at some journals.



Pre- pandemic:  
Peer review 100 days +  
production 24 days =  
median > 4 months from  
submission to  
publication.

## PRODUCTION TIME

The same analysis of Pubmed papers suggests that the time between acceptance and publication has dropped, probably because technology has improved.



*Nature* **530**, 148–151 (11 February 2016) doi:10.1038/530148a

# Rapid Recommendations and Living Systematic Reviews

Practice » Rapid Recommendations

## A living WHO guideline on drugs for covid-19

BMJ 2020 ; 370 doi: <https://doi.org/10.1136/bmj.m3379> (Published 04 September 2020)

Cite this as: BMJ 2020;370:m3379


### Visual summary of recommendation

#### Population

This recommendation applies only to people with these characteristics:




Patients with confirmed covid-19



#### Interventions compared

Usual supportive care	Corticosteroids Suggested regimen	Acceptable alternative regimens
-----------------------	--------------------------------------	---------------------------------

## Rapid Recommendations process step by step (with target times)



#### Citation tools

Request permissions

Author citation

Add article to BMJ Portfolio

Email to a friend

Topics



# Covid: the first preprinted epidemic. Will it help?


Waste in covid-19 research: how do we make the outpouring of research more effective?



## Waste in covid-19 research

A deluge of poor quality research is sabotaging an effective evidence based response The medical research world is responding to the covid-19 pandemic...  
bmj.com

Paul Glasziou, Sharon Sanders, Tammy Hoffmann,  
BMJ 2020;369:m1847 doi: [10.1136/bmj.m1847](https://doi.org/10.1136/bmj.m1847)



# Thank you!

Web: [bmj.com](https://bmj.com)

Email: [tbloom@bmj.com](mailto:tbloom@bmj.com)

Twitter: [@TheoBloom](https://twitter.com/TheoBloom)

[medrxiv.org](https://medrxiv.org)

[@medrxivpreprint](https://twitter.com/medrxivpreprint)



Cold  
Spring  
Harbor  
Laboratory

— Yale —

BMJ /